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Abstract  21 
Background: Muscle wasting in the critically ill is up to 2% per day and delays 22 
patient recovery and rehabilitation. It is linked to inflammation, organ failure and 23 
severity of illness. The aims of this study were to understand the relationship between 24 
muscle depth loss, and nutritional and inflammatory markers during prolonged critical 25 
illness. Secondly, to identify when during critical illness catabolism might decrease, 26 
such that targeted nutritional strategies may logically be initiated. 27 
Methods: This study was conducted in adult intensive care units in two large 28 
teaching hospitals. Patients anticipated to be ventilated for >48 hours were included. 29 
Serum C-reactive protein (mg/L), urinary urea (mmol/24h), 3-methylhistidine 30 
(µmol/24h) andnitrogen balance (g/24h) were measured on days 1, 3, 7 and 14 of the 31 
study.  Muscle depth (cm) on ultrasound were measured on the same days over the 32 
bicep (bicep and brachialis muscle), forearm (flexor compartment of muscle) and thigh 33 
(rectus femoris and vastus intermedius).   34 
Results: Seventy-eight critically ill patients were included with mean age of 59 35 
years (SD: 16) and median Intensive care unit (ICU) length of stay of 10 days (IQR: 6-36 
16). Starting muscle depth, 8.5cm (SD: 3.2) to end muscle depth, 6.8cm (SD: 2.2) 37 
were on average significantly different over 14 days, with mean difference -1.67cm 38 
(95%CI: -2.3 to -1cm), p<0.0001. Protein breakdown and inflammation continued over 39 
14 days of the study.  40 
Conclusion: Our patients demonstrated a continuous muscle depth loss and 41 
negative nitrogen balance over the 14 days of the study. Catabolism remained 42 
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dominant throughout the study period. No obvious ‘nutritional tipping point” to identify 43 
anabolism or recovery could be identified in our cohort. Our ICU patient cohort is one 44 
with a moderately prolonged stay. This group showed little consistency in data, 45 
reflecting the individuality of both disease and response. The data are consistent with 46 
a conclusion that a time based assumption of a tipping point does not exist. Trial 47 
Registration: International Standard Randomised Controlled Trial Number: 48 
ISRCTN79066838. Registration 25 July 2012. 49 
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A problem common to virtually all intensive care unit (ICU) patients is the deterioration 55 
in nutritional and functional status during and after their ICU stay, which has been 56 
identified as a research priority (1; 2). In survivors of the acute respiratory distress 57 
syndrome (ARDS) muscle weakness and fatigue determined long-term outcome, it 58 
was shown that recovery time should be measured in months to years rather than 59 
days to weeks (3). Muscle wasting and weakness were still evident one year after ICU 60 
discharge in this cohort (3), whilst physical disability had been identified up to five 61 
years later, with exercise capacity only reaching 76% of the predicted value (4). In a 62 
similar cohort of ARDS survivors weight and fat mass increased 1 year after ICU 63 
admission, whilst lean mass losses had not yet recovered (5). 64 
Muscle wasting during critical illness is a multi-factorial process thought to be a 65 
consequence of sepsis and inflammation, disuse atrophy, severity of illness (6;7) and 66 
hypoxia per se (8). Muscle wasting may also be associated with increased cytokine 67 
levels (9, 10) and glucocorticoid administration (11). Muscle protein breakdown rates 68 
remained high over the first week of critical illness, whilst muscle protein synthesis 69 
appeared to return to the level of a healthy fasted controls after seven days (7, 12).  70 
Muscle mass declines early and rapidly, up to  2% per day during ICU stay (5, 7,13) 71 
with significantly higher rates of wasting seen in patients with multi-organ failure than 72 
those presenting in single organ failure (7). For the elderly, who are increasingly 73 
represented in the intensive care population, these losses may be in addition to age-74 
related losses and will seriously compromise recovery to independence. Low skeletal 75 
muscle mass and poor muscle quality on admission to the ICU has been shown to be 76 
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a risk factor for mortality (14; 15). Simply delivering more nutrients to critically ill 77 
patients does not appear to ameliorate muscle wasting (7, 11). 78 
A recent research agenda review paper highlighted the need to distinguish between 79 
the different phases of critical illness (catabolic vs. anabolic phase) to help identify 80 
patients’ “readiness for enhanced feeding” (16). Targeting nutritional strategies in the 81 
very acute catabolic phase may be counter-productive as over-feeding may be harmful 82 
(17). Targeting interventions once peak catabolism has started to wane could 83 
therefore potentially support patients into a recovery phase without doing any harm. 84 
The aims of this exploratory research were two-fold: 85 
1. To explore the relationship between muscle depth loss (measured via 86 
ultrasound) and nutritional and inflammatory markers during prolonged critical 87 
illness using standard bedside equipment. 88 
2. To identify when during prolonged critical illness catabolism might decrease 89 
such that targeted nutritional or pharmacological strategies could be initiated. 90 
 91 
 92 
Materials and methods 93 
The study received a favourable ethical review from Camden & Islington Research 94 
Ethics Committee (10/H0722/40), which included approval of the consent procedure 95 
for patients lacking capacity. This study was conducted in four adult intensive care 96 
units (mixed medical, surgical and trauma patients) in two large London teaching 97 
hospitals from September 2010 to February 2013. All patients anticipated to be 98 
ventilated for >48 hours were considered for inclusion into this study. Participants were 99 
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excluded if they were permanently wheelchair bound; were not able to provide 100 
retrospective consent due to learning difficulties, psychiatric reasons or dementia; 101 
were receiving long term steroid treatment, had severe Parkinson’s disease, had 102 
bilateral amputations or if they were pregnant. 103 
Descriptive measures: Serum C-reactive protein (CRP), urinary urea and 3-104 
methylhistidine (3-MH), nitrogen balance and total muscle depth were measured 105 
serially in patients.  106 
Muscle depth change (cm) was measured using a Sonosite M Turbo™ ultrasound 107 
machine with a 5 MHz linear array transducer (Sonosite Ltd, Hitchin, Hertfordshire, 108 
UK). Muscle depth change was assessed over the bicep, forearm and thigh following 109 
the protocol described by Reid et al (13). Reid provided training to the investigator 110 
using the following protocol:  111 
Participants were supine with measurements made on the right side of the body, on 112 
the bicep, forearm and thigh to mark a halfway point on the limb from which the 113 
ultrasound measurement would be made. Markings were made in indelible ink to 114 
ensure that the same site would be measured throughout the patient’s ICU stay. Three 115 
ultrasound measurements were made per site using the built-in electronic calliper on 116 
a frozen real-time cross-sectional image. The average of three measurements for each 117 
site was used, up to a 0.2cm difference was accepted. The mean value from the bicep, 118 
forearm and thigh was combined to provide a daily total muscle depth (cm). A 119 
substantial amount of ultrasound gel was applied to ensure that the probe could rest 120 





The elbow was flexed to 90degress and a point on the skin was marked between the 124 
tip of the olecranon and the acromion with indelible ink. With the elbow extended and 125 
the patient in a supine position, the forearm was supinated. The ultrasound probe was 126 
applied at the pen mark on the upper arm to obtain a cross-sectional (axial) view which 127 
included the humerus, biceps and brachialis muscle, subcutaneous tissue and skin.  128 
Forearm: 129 
The patient’s arm was extended and forearm kept in supinated position. A point 130 
between the antecubital skin crease and the ulnar styloid was marked with indelible 131 
pen. The ultrasound probe was applied at the pen mark on the radial (lateral) side of 132 
the forearm to obtain a cross-sectional (axial) view which included the radius. The 133 
thickness of the flexor compartment was measured anteriorly between the superficial 134 
fat-muscle interface and the interosseous membrane; radial or lateral side of the 135 
forearm. 136 
Thigh: 137 
The patient was supine with knee extended. A halfway point on the thigh was identified 138 
and marked. The thickness of the quadriceps muscle group anteriorly between the 139 
superficial fat-muscle interface and the femur was measured (Vastus intermedius and 140 
Rectus Femoris). The ultrasound probe was applied at the pen mark on the anterior 141 
surface of the thigh to obtain a cross-sectional (axial) view which included the femur, 142 
quadriceps muscles, subcutaneous tissue and skin. 143 
Reliability tests were performed between investigators prior to conducting this study, 144 
intra-class correlation coefficients were 0.984, 95%CI (0.958-0.993) and 0.965, 95%CI 145 
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(0.882-0.990) respectively for intra- and inter-rater assessments, indicating good 146 
reliability. Bland Altman data for intra-rater assessment: mean difference -0.05cm, 147 
95% upper limit: 0.73cm, 95% lower limit: -0.83cm. Bland Altman data for inter-rater 148 
assessment: mean difference 0.02cm, 95% upper limit: 1.04cm, 95% lower limit -149 
1.00cm. 150 
C-reactive protein (mg/L) was measured from plasma samples collected on days 1, 3, 151 
7 and 14 of the study. Urinary studies from study days 1, 3, 7 and 14 were analysed 152 
in accredited clinical laboratories and included analysis of 3-methylhistidine 153 
(µmol/24h), as a surrogate marker for skeletal muscle breakdown, and urinary urea 154 
(mmol/24h). Urinary 3-methylhistidine was selected as it appears almost solely in 155 
skeletal muscle protein and is not re-used.  156 
Urinary 3-methylhistidine were analysed using an amino acid analyser with cation 157 
exchange chromatography (JEOL UK Ltd., Hertfordshire, UK). Samples were 158 
analysed using ninhydrin detection and one inferred standard to quantify amino acid 159 
content. External quality assurance was provided by ERNDIM Quantitative Amino Acid 160 
Scheme. Urine urea was measured by a kinetic urease using an Abbott Architect 161 
assay with Abbott reagents (Abbott Diagnostics, Berkshire, UK). External quality 162 
assurance was provided by UKNEQAS Urine Chemistries Scheme. No reference 163 
ranges are provided for urinary urea or 3-MH excretion per 24h. 164 
Nitrogen balance (g/day) was calculated using both the British Dietetic Association’s 165 
Parenteral and Enteral Nutrition Group (18) recommended equation and the Deacon 166 
equation (19) for estimating nitrogen excretion, assuming nitrogen balance equals 167 




Nitrogen balance equations 170 
The British Dietetic Association’s Parenteral and Enteral Nutrition Group (PENG) nitrogen balance 171 
equation (18):  172 
urinary urea (mmol/24h) x 0.033 + obligatory losses (2-4g nitrogen/24h for hair, skin and faecal losses). 173 
Add 0.6g nitrogen per 1 degree above 37.5°C. 174 
The Deacon equation for nitrogen balance:  175 
urea excretion (mmol/24h) x 0.028. Add 20% for other urinary losses and a further 2g/day for losses by 176 
other routes (19). 177 
Weight (kg), height (m) and body mass index (kg/m2) data were recorded in addition 178 
to daily energy (kcal) and protein (grams) intakes. Recent weights and heights were 179 
obtained from medical notes. If this was not available family members were asked or 180 
weight was estimated by an experienced dietitian. If height data was not available 181 
heights were estimated from obtaining ulnar length (measured from the acromion to 182 
the ulnar styloid). Enteral feed tolerance was monitored by assessing gastric residual 183 
volumes (ml) and incidence of vomiting. Patients were fed within 48h of ICU admission 184 
according to the local ICU feeding protocol; energy requirements were calculated with 185 
predictive equations (20; 21) and Propofol derived energy was included. No indirect 186 
calorimetry was available. Protein requirements were estimated at 1.2-1.5g/kg/day 187 
(21; 22). 188 
Statistical analysis: Continuous data were tested for normality and presented 189 
as mean (SD), mean (95% confidence intervals) or median (IQR). Categorical data 190 
are presented as frequencies. Correlations were performed using the Spearman’s 191 
rank correlation test for non-parametric data. The difference between starting muscle 192 
depth to end muscle depth was calculated by paired t-test. Descriptive statistical 193 
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analyses were performed using GraphPad Prism 6.02 for Windows (GraphPad 194 
Software, La Jolla, CA). For missing data a ‘last observation carried forward’ approach 195 
was followed. A comparison of data over the first vs. the second week of study was 196 
also performed using the Wilcoxon matched-pairs signed rank test, GraphPad Prism 197 
6.02 for Windows (GraphPad Software, La Jolla, CA). Significance was set at 0.05. 198 
 199 
Results 200 
Eighty patients were recruited to the study, two died prior to testing, 78 were included 201 
in the final analysis, Fig 1. ‘Other’ exclusions (Fig 1) refer to patients unable to provide 202 
retrospective consent due to learning difficulties or dementia, patients enrolled into 203 
other studies, patients receiving long-term steroids and previously wheelchair bound 204 
patients.    205 
Fig 1. Patient recruitment on ICU .   206 
The 78 patients were representative of longer- staying patients in mixed medical and 207 
surgical intensive care units (Table 1) with mean (SD) age of 59 (16) years, 208 
predominantly male (69%), with a mean (SD) APACHE II score of 21.6 (7.7) and 209 
median (IQR) ICU length of stay of 10 (6-16) days. Patients were recruited within 72h 210 
of their ICU admission; ‘Day 1’ refers to day 1 of study, which occurred between days 211 
1-3 of the patient’s ICU admission. APACHE II score was determined according to day 212 





Table 1. Patient demographics (N=78). 216 











26 (22 -31) 




ICU Length of stay (days) 
Median (IQR) 
 
10 (6 -16) 
Diagnostic categories - ICU 
admission: 
 
Pneumonia 19 (24%) 
Cardiology/Cardiac surgery 14 (18%) 
Neurology/neurosurgery 9 (11%) 
Sepsis/Septic Shock 8 (10%) 
Vascular surgery 6 (7.6%) 
Major Trauma 6 (7.6%) 
Traumatic Brain Injury 6 (7.6%) 
Gastroenterology 3 (3.8%) 
Gastrointestinal Surgery 3 (3.8%) 
HIV 2 (2.5%) 
Multi-organ failure 1 (1.3%) 
Renal Failure 1 (1.3%) 
ICU: Intensive Care Unit; SD: standard deviation; IQR: interquartile range; BMI: Body Mass Index; APACHE II: Acute 217 
physiological and chronic health evaluation II; HIV: Human immunodeficiency virus. 218 
 219 
The flow of patients through the study is summarised in Fig 2, illustrating numbers 220 
achieved for each test day. Twenty-three patients (29%) died in ICU. Four patients 221 
(5%) died in hospital after ICU discharge. 222 
 223 
Fig 2. CONSORT diagram for patient discharges, deaths and patients not 224 
measured. USS: ultrasound scanning; CRRT: Continuous Renal Replacement Therapy. Blood tests: C - reactive protein 225 
and serum albumin. Urine testing not performed: day 1 (6 misplaced samples, 14 patients anuric/CRRT), day 3: (7 misplaced 226 
samples, 23 patients anuric/CRRT), day 7: (4 misplaced samples, 14 patients anuric/CRRT); day 14: (3 patients anuric/CRRT). 227 
 228 
There was a significant reduction in muscle depth as measured by ultrasound, over 7 229 
and 14 days (using all available data) presented in Table 2. This data includes the 230 
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total of three sites, the bicep (bicep and brachialis muscle), forearm (flexor 231 
compartment of muscle) and thigh (rectus femoris and vastus intermedius). Table 3 232 
shows the clinical characteristics of long stay patients (N=17) studied over 14 days on 233 
ICU. 234 
Table 2. Muscle depth change (total of three sites bicep, forearm, thigh). 235 
  N=43 over 7 days 
 













6.5 (3.1) * 
 







-1.1 (-1.5 to -0.7) 
<0.0001 
-1.67 (-2.3 to -1) 
<0.0001 















Table 3. Clinical characteristics of long stay patients studied for 14 days (N=17) 249 
AAA: abdominal aortic aneurysm; AF: atrial fibrillation; ALD: alcoholic liver disease; CABG: coronary artery bypass graft; COPD: 250 
chronic obstructive pulmonary disease; DM: Diabetes Mellitus; ESRF: end stage renal failure; ETOH: ethanol misuse; HD: 251 
haemodialysis; HTN: hypertension; IHD: ischaemic heart disease; LOS: length of stay; MI: myocardial infarction; MOF: multi-252 
organ failure; MSSA: Methicillin-sensitive Staphylococcus aureus; MV: mechanical ventilation; PVD: peripheral vascular disease; 253 
SAH: subarachnoid haemorrhage; TURP: transurethral resection of the prostate; VF: ventricular fibrillation 254 
 255 







1 72 F Emergency AAA repair, MOF DM II; High cholesterol, HTN 24 7 40 
2 73 F Laparotomy: ischemic small bowel, 
cardiac arrest. MOF 
MI, PVD, IHD, Parkinson’s, COPD 17 31 
51 
3 59 F Poor grade SAH for coiling, chest 
sepsis, MOF 
Nil, previously fit and well 26 18 
26 
4 52 M Pancreatitis, chest sepsis, MOF Pancreatitis, ETOH, GORD, cholesterol, 
Cholecystectomy'09, smoker 10/d 
17 38 
57 
5 80 M VF arrest post CABG, cardiogenic 
shock, MOF 




6 53 M Reduced GCS, seizures, MOF  Decompensated ALD, encephalitis, 




7 57 F Lithium toxicity Psychotic depression, Bell’s palsy 21 14 19 
8 28 M Myocarditis due to pneumonia  Nil 14 26 27 
9 44 M PEA arrest, chronic pancreatitis, 
MOF 
Chronic pancreatitis, 28yr ETOH history 29 37 
37 
10 55 F MSSA septicaemia Large intra-abdominal cystic mass 9 9 17 
11 85 F Sepsis secondary to myeloma, 
Encephalitis 
HTN, multiple myeloma - chemo 13 8 
17 
12 85 M Emergency AAA repair HTN, cholesterol, angina 16 25 25 
13 24 F Traumatic brain injury, MOF Nil 24 17 21 
14 40 M Alcoholic Liver Disease, MOF ALD 26 40 40 
15 73 F Chest infection DM, HTN 14 22 24 
16 77 M Emergency AAA repair + open 
abdomen, MOF 
HTN 27 104 
108 
17 32 M Major Trauma Nil 18 14 16 
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A strong association was observed between blood concentration of CRP and % 256 
muscle depth loss at day 14 (r = -0.66, p=0.017). No correlation was observed between 257 
% muscle depth loss and age:     r = -0.04, p=0.8; APACHE II score: r = -0.124, p=0.44; 258 
SOFA score: r = -0.14, p=0.40 and nitrogen loss: r = -0.02, p=0.92.  259 
The biochemical data suggest that a catabolic state persists up to the end of the 14 260 
days data collection with raised inflammatory markers, progressive protein breakdown 261 
and continuing loss of muscle depth (Figs 4-7). Fig 7a shows the negative nitrogen 262 
balance in the study cohort (N=55) and Fig 7b demonstrates this negative balance in 263 
the long stay patients only (N=14). Protein losses were included in calculations in Fig 264 
7a and b. Visual representation of median values for urinary urea, percentage muscle 265 
depth loss, 3-MH and CRP (Figs 3-6) in long stay patients all suggest a persisting 266 
catabolic state up to day 14, as does the continuing negative nitrogen balance (Fig 7a 267 
and b), however of interest is the small change in trajectory of inflammatory and 268 
catabolic markers in the second week of the study data. Markers appear to improve 269 
from day 7 to 14. Median change (IQR) over 14 days is presented in a Supporting 270 
information, S1 - S3 Tables. 271 
 272 
Fig 3. Serial CRP (N=17) measurements in long stay patients: (i) Plots to explore 273 
individual variability (ii) Box plots reported with median and IQR. * CRP: C-reactive 274 
protein. Medians and IQR are reported in the Supplementary Table (a), not on this figure due to wide variance. 275 
 276 
Fig 4. Serial urinary urea (N=14) measurements in long stay patients: (i) Plots to 277 
explore individual variability (ii) Box plots reported with median and IQR. 278 
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Fig 5. Serial 3MH (N=14) measurements in long stay patients: (i) Plots to explore 279 
individual variability (ii) Box plots reported with median and IQR. 3-MH: 3-methylhistidine. 280 
Medians and IQR are reported in the Supplementary Table (a), not on this figure due to wide variance. 281 
 282 
Fig 6. Serial % muscle depth change (N=17) measurements in long stay patients: 283 
(i) Plots to explore individual variability (ii) Box plots reported with median and 284 
IQR.   285 
 286 
Fig 7. Nitrogen balance in (a) whole study cohort (N=55) and (b) long stay 287 
patients (N=14) over 14 days. 288 
 289 
In four of our patients that remained in ICU over 14 days the reduction in Day 14 CRP 290 
did not correspond with a change in surrogates for catabolism (urinary urea and 3-291 
MH) with day 14 results still raised, Table 4. 292 
 Table 4. Cases where CRP reduced at Day 14 whilst surrogate markers for 293 
catabolism (urinary urea and 3-MH) remained high. 294 
 295 
 296 
Patient CRP1 CRP7 CRP14 UUrea1 UUrea7 UUrea14 3MH1 3MH7 3MH14 
1 68.1 71.3 3 46 183 266 471 380 224 
2 110 211.9 48.2 221.2 436.59 277.76 244 342 233 
3 64.6 32.4 27 153 528.2 182 183 333 102 
4 279.1 210.9 13.8 473.3 723 802.8 305 299 556 
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Energy balance (difference between estimated energy targets via predictive equations 297 
and energy intake) and protein balance (difference between estimated protein targets 298 
and protein intake) in patients remaining on the unit for ≥7 days (N=43) is shown in 299 
Fig 8. Energy (and protein) targets were estimated as no indirect calorimetry was 300 
available in this study. 301 
Fig 8. Predicted energy and protein balance of patients on the unit for ≥7 days 302 
(N=43) over 14 days. 303 
Data were also compared between the first week and the second week of study, and 304 
although they were not found to be significantly different between the two weeks, 305 
graphical representation appears to suggest a modest difference, Fig 9. 306 
Fig 9. Data comparing the first versus the second week of study: urinary urea 307 
(N=14), 3-MH (N=14), CRP (N=17) and muscle loss (N=17). 308 
 309 
Discussion 310 
Our observational study focused on patients with a prolonged stay in ICU; the median 311 
length of stay in our study is longer than national or international figures, because we 312 
recruited only patients expected to be ventilated for >48 hours. These are patients with 313 
greater original insults or more complications that result in longer lengths of stay. This 314 
is illustrated by the day 14 data when 17 study patients still remained on ICU; 11 of 315 
these remained ventilated, two were on non-invasive ventilation, and four were self-316 
ventilating. Although long stay patients may only represent a small group, they are an 317 
important cohort as they are resource intensive and may have outcomes that are 318 
worse than patients with an ICU stay of less than 10 days (23). 319 
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This is the first study, to our knowledge, that used clinical markers for inflammation, 320 
nutrition and catabolism in conjunction with muscle depth change measured by 321 
ultrasound to explore metabolic state during a period of critical illness. Results 322 
demonstrate progressive muscle depth loss (Table 2), negative nitrogen balance (Fig 323 
7), continued catabolism and marginal improvement of inflammation, in patients who 324 
survive beyond 7 days (Figs 3-6). These results demonstrate an intense catabolic 325 
state in line with others’ work (24;25).  326 
Our data are however highly heterogeneous with substantial individual variation. 327 
Inspection of our data does not appear to show an obvious "nutrition tipping point" 328 
within the studied cohort where anabolism or recovery could be identified, granted 329 
within a modest sample size. Additionally, the suggestion that CRP could potentially 330 
be used as a surrogate to define recovery or anabolism as inflammation subsides, has 331 
not been shown in our data. There appears to be a lack of relationship between CRP, 332 
which was used as a surrogate for inflammatory state, and markers of catabolism and 333 
muscle breakdown (24hr urinary urea and 3-MH). For some of the patients day 14 334 
CRP results had effectively normalised yet day 14 urinary urea and 3MH were still 335 
significantly raised, indicating ongoing catabolism. This points to the need for 336 
individual monitoring using a number of markers to understand catabolism. 337 
Although we initially aimed to identify a ‘nutritional tipping point’, which could be used 338 
to predict whether patients remained catabolic or not using logistic regression, it was 339 
difficult to define ‘catabolism’ accurately from the markers measured in this study. If 340 
nitrogen balance, urinary urea and urinary 3-methylhistidine are used as surrogates 341 




Enteral feeding should commence early in the critically ill, within 24-48h of ICU 344 
admission (21; 22), what is less clear is how much we should feed patients during the 345 
first weeks of illness. Tailoring energy targets to the metabolic phase of critical illness 346 
is widely discussed (16; 26), however determining how to identify the phases remains 347 
challenging. It has been recognised that a ‘dynamic marker’ is required to help identify 348 
which patients might be ready for increased feeding. This type of marker would ideally 349 
be able to track changes in endocrine and metabolic markers (16).  Yet there is no 350 
agreed definition on the exact description of the phases, when they might occur or 351 
how one would identify the transition point between them. ESPEN guidelines (21) 352 
recently expanded the definition beyond the ‘ebb’ and ‘flow phase’, with an early acute 353 
phase (where patients have metabolic instability and with increasing catabolism) and 354 
a late acute phase (where metabolic disturbances have started to settle down whilst 355 
significant muscle wasting is observed). Beyond 7 days has been defined as the ‘post-356 
acute phase’ in which patients either progress onto rehabilitation, or remain in a 357 
‘persistent inflammatory or catabolic state’, which will require a prolonged period of 358 
hospitalisation (21). Regardless of the definition used our impression is that 359 
identification of these phases and the transition points between them will be very 360 
challenging to determine, particularly at a population level. We believe that there is 361 
need to move towards a more individualistic system, but how this can be achieved 362 
remains uncertain.  Whether metabolomic profiling could be used as future way to 363 
distinguish metabolic phases (26) remains to be seen. 364 
It is also not yet known whether catabolism could be reduced early, or at all during ICU 365 
stay. Future strategies to reduce early catabolism might require as yet unidentified 366 
pharmacological interventions or, more speculatively, nutritional interventions coupled 367 
with physical activity or a combination thereof. Timing, dose and duration of nutritional 368 
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intervention are all important factors to consider in future studies. Nutritional 369 
interventions combined with physical activity would likely provide the best opportunity 370 
for recovery, since muscle anabolism is enhanced by the synergistic action of amino 371 
acids and resistance exercise (27-29).  How nutritional interventions and physical 372 
activity relate to longer term physical and functional recovery of ICU patients also 373 
needs to be explored. 374 
Our patients lost on average 1.2% of muscle depth per day over 14 days, which 375 
confirms previous studies that report muscle depth losses between 1-2% per day 376 
(7;13). Reid et al (13) reported a median 1.6% muscle depth loss per day in 48 ICU 377 
patients over 7 days, and Puthucheary et al (7) showed muscle losses, in patients with 378 
similar demographics to the current study, of 1.7% per day over 10 days. This group 379 
also showed that muscle breakdown remained elevated during the first week on ICU, 380 
whilst synthesis returned to normal by the end of the first week (7). Patients in this 381 
cohort were in negative energy and protein balance (Fig 8), a common finding in many 382 
recent clinical trials in ICU (30-32). Negative energy and protein balances will 383 
contribute to muscle depth loss and catabolism, however they are unlikely to be the 384 
sole cause of ICU-related muscle wasting (13;33).  385 
Muscle ultrasound offers a practical and feasible method to serially quantify muscle 386 
mass or volume change in the ICU environment, in even the sickest patients. 387 
Ultrasound can have large inter-observer variability (22), however reliable measures 388 
are possible and have previously been reported (34). When using this technique it is 389 
vital to ensure assessors are fully trained and intra and inter-rater reliability is tested. 390 
We carried out extensive training and found good intra- and inter-rater reliability was 391 
achieved by our assessors. A recent systematic review highlights the increased 392 
potential value and excellent reported reliability of muscle ultrasound (34).  393 
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As with all clinical studies undertaken in the intensive care environment there are a 394 
number of limitations. As previously mentioned this study cohort consisted of a group 395 
of patients with a moderately prolonged stay on ICU, which limits the wider applicability 396 
of the findings. The attrition of patients from the study cohort due to discharge from 397 
ICU to wards has meant a large amount of missing data at later time points, 398 
complicating the interpretation of the data. We were unable to follow patients up on 399 
the wards due to limited resources. We would recommend that follow up after 400 
discharge from ICU should be included in future research. Similarly mortality in the 401 
study cohort made data interpretation more difficult as some of the data presented is 402 
from patients who ultimately died. Additionally, patients on continuous renal 403 
replacement therapy were excluded from urine collection studies. Protein losses in the 404 
critically ill could be underestimated from urinary urea (35), and muscle breakdown 405 
may not be the sole contributor to 3-MH excretion as actin is present in other cells 406 
(36). Additionally, as 3-MH is derived from actin and myosin, breakdown reflects that 407 
of all muscle which may include skeletal, smooth and cardiac muscle. Using 3-MH as 408 
a surrogate measure for muscle breakdown in conjunction with other outcome 409 
measures to detect muscle or protein breakdown may reduce this limitation. Energy 410 
expenditure was estimated using predictive equations rather than measured by 411 
indirect calorimetry as calorimetry was not available. Energy and protein balances may 412 
appear artificially low in our study as balances were calculated over a 24h period rather 413 
than accounting for part days on the ICU. Finally, day 1 of study may not necessarily 414 
be the first day of the patient’s ICU admission (median ICU stay at day 7 of study was 415 





Strategies to limit muscle loss are much needed in this population to aid recovery, and 419 
the timing of such strategies may be crucial to their success. Our patients 420 
demonstrated a continuous muscle depth loss and negative nitrogen balance over the 421 
14 days of the study. Catabolism remained dominant throughout the study period 422 
whilst there appeared to be a marginal improvement in inflammation. No obvious 423 
‘nutritional tipping point” to identify anabolism or recovery could be identified in our 424 
cohort. Our ICU patient cohort is one with a moderately prolonged stay; a very 425 
important group due to their high resource requirement. This group showed little 426 
consistency in data, reflecting the individuality of both disease and response. Thus the 427 
data are consistent with a conclusion that a time based assumption of a tipping point 428 
does not exist. This supports an argument for individually characterising patient state 429 
and personalising the approach; be that with a yet to be identified metabolic marker, 430 
a novel method or a device. 431 
 432 
Key messages 433 
 In this ICU patient cohort with moderately prolonged stay, catabolism remained 434 
elevated throughout 14 days follow up even though inflammation improved 435 
marginally.  436 
 CRP does not appear to be a good surrogate marker to assess anabolism and 437 
recovery. 438 
 Our data did not demonstrate an obvious time point where anabolism starts to 439 
exceed catabolism or ‘nutritional tipping point’. 440 
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APACHE II: Acute Physiology and Chronic Health Evaluation score II; ARDS: acute 445 
respiratory distress syndrome; CRP: C - reactive protein; ICU: Intensive care unit; IQR: 446 
Interquartile range; 3-MH: 3-methylhistidine; PENG: parenteral and enteral nutrition 447 
group; SOFA: Sequential Organ Failure Assessment. 448 
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